REGN: Regeneron Pharmaceuticals Inc. Stocks News on November 15, 2025

Bristol Myers Slouches 4% After Experts Say Its Heart Drug Will Fail

REGN

Investor's Business Daily

a day ago

Bristol Myers Slouches 4% After Experts Say Its Heart Drug Will Fail

Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

REGN

The Fly

2 days ago

Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

REGN

GlobeNewswire

2 days ago

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

REGN

MT Newswires

3 days ago

Scotiabank Initiates Regeneron Pharmaceuticals at Sector Perform With $650 Price Target

Here Are the Top Growth Healthcare Stocks Every New Investor Should Know

REGN

Motley Fool

3 days ago

Here Are the Top Growth Healthcare Stocks Every New Investor Should Know

REGN

Morningstar Research

3 days ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

REGN

Simply Wall St.

4 days ago

Regeneron (REGN): Revisiting Valuation After Recent 16% Share Price Rally

Merck’s Heart Pill Slashes Cholesterol Levels in Test Patients

REGN

Barrons.com

5 days ago

Merck’s Heart Pill Slashes Cholesterol Levels in Test Patients

REGN

MT Newswires

5 days ago

European Equities Close Sharply Higher in Monday Trading on Hopes for End to US Government Shutdown

REGN

MT Newswires

5 days ago

Alvotech Wins UK Court Ruling Allowing Production of Biosimilar to Eylea

REGN

Clinical Trials Arena

5 days ago

Dupixent set for ninth US approval after Phase III AFRS success

REGN

StockStory

6 days ago

Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks

UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)

REGN

GlobeNewswire

6 days ago

UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)

REGN

Simply Wall St.

7 days ago

How Positive Phase 2 Results for Novel Antibodies at Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%

REGN

Investor's Business Daily

7 days ago

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

REGN

GlobeNewswire

7 days ago

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

REGN

Morningstar Research

8 days ago

Analyst Report: Intellia Therapeutics, Inc.

REGN

MT Newswires

8 days ago

UBS Adjusts Price Target on Regeneron Pharmaceuticals to $660 From $595, Maintains Neutral Rating

Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble

REGN

Zacks

8 days ago

Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble

REGN

MT Newswires

8 days ago

Regeneron, Sanofi Say Dupixent for Allergic Fungal Rhinosinusitis Met Primary Endpoint in Phase 3 Study

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

REGN

GlobeNewswire

8 days ago

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

REGN

GlobeNewswire

8 days ago

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates

REGN

GlobeNewswire

9 days ago

Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates

Life Sciences, TechBio, and Investment Leaders at Demy-Colton’s BioFuture™ 2025 Suggest Health and Biotech Sectors Show Signs of New Life

REGN

Business Wire

9 days ago

Life Sciences, TechBio, and Investment Leaders at Demy-Colton’s BioFuture™ 2025 Suggest Health and Biotech Sectors Show Signs of New Life

Assessing Regeneron After New Drug Pipeline Expansions and Double-Digit Share Price Decline

REGN

Simply Wall St.

10 days ago

Assessing Regeneron After New Drug Pipeline Expansions and Double-Digit Share Price Decline

Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y

REGN

Zacks

10 days ago

Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y

Michael Burry Is Super-Bearish On Palantir — With 5 Million Puts

REGN

Benzinga

11 days ago

Michael Burry Is Super-Bearish On Palantir — With 5 Million Puts

5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call

REGN

StockStory

12 days ago

5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call

Regeneron Announces Investor Conference Presentations

REGN

GlobeNewswire

12 days ago

Regeneron Announces Investor Conference Presentations

2 Beaten-Down Stocks That Could Be About to Rally

REGN

Motley Fool

12 days ago

2 Beaten-Down Stocks That Could Be About to Rally

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%

REGN

Motley Fool

13 days ago

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%

REGN

MT Newswires

15 days ago

Regeneron Pharmaceuticals Insider Sold Shares Worth $4,252,745, According to a Recent SEC Filing

Is OPKO’s Regeneron Deal and Asset Sale Shifting the Investment Case for OPKO Health (OPK)?

REGN

Simply Wall St.

15 days ago

Is OPKO’s Regeneron Deal and Asset Sale Shifting the Investment Case for OPKO Health (OPK)?

REGN

MT Newswires

15 days ago

Rothschild & Co Redburn Adjusts Price Target on Regeneron Pharmaceuticals to $910 From $900

‘Sometimes the only winning move is not to play,’ says Michael Burry in bubble warning

REGN

MarketWatch

15 days ago

‘Sometimes the only winning move is not to play,’ says Michael Burry in bubble warning

AstraZeneca’s gMG drug fails to fend off rivals despite Phase III win

REGN

Clinical Trials Arena

15 days ago

AstraZeneca’s gMG drug fails to fend off rivals despite Phase III win

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

REGN

GlobeNewswire

16 days ago

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential

REGN

PR Newswire

16 days ago

JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential

Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals

REGN

Insider Monkey

16 days ago

Opko Health Inc.’s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals

REGN

Morningstar Research

16 days ago

Analyst Report: Intellia Therapeutics, Inc.

REGN

Simply Wall St.

16 days ago

Regeneron (REGN) Margin Compression Reinforces Cautious Community Narratives Heading Into Earnings Season

What Catalysts Are Driving the Changing Narrative for Regeneron?

REGN

Simply Wall St.

16 days ago

What Catalysts Are Driving the Changing Narrative for Regeneron?

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

REGN

GlobeNewswire

17 days ago

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

REGN

Morningstar Research

17 days ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher?

REGN

Barrons.com

17 days ago

Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher?

REGN

MT Newswires

17 days ago

OPKO's ModeX, Regeneron Collaborate to Develop Antibodies for Therapeutic Indications

FDA rejects Regeneron’s pre-filled Eylea HD syringes amid filling facility woes

REGN

Pharmaceutical Technology

17 days ago

FDA rejects Regeneron’s pre-filled Eylea HD syringes amid filling facility woes

REGN

MT Newswires

17 days ago

RBC Raises Price Target on Regeneron Pharmaceuticals to $708 From $704, Keeps Sector Perform Rating

OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications

REGN

GlobeNewswire

17 days ago

OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications

REGN

MT Newswires

18 days ago

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $725 From $640, Maintains Outperform Rating

Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts

REGN

Investor's Business Daily

18 days ago

Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts

Intellia Therapeutics (NTLA) Is Down 45.2% After Pausing Key Nex-z Trials Over Safety Issue – Has The Bull Case Changed?

REGN

Simply Wall St.

18 days ago

Intellia Therapeutics (NTLA) Is Down 45.2% After Pausing Key Nex-z Trials Over Safety Issue – Has The Bull Case Changed?

REGN

MT Newswires

18 days ago

US Equity Indexes Break Records as Fed Set to Cut While Gains Accrue From Earnings, Corporate Actions

REGN

Motley Fool

18 days ago

Regeneron (REGN) Q3 2025 Earnings Call Transcript

REGN

MT Newswires

18 days ago

US Equity Markets End Higher Amid Expectations of Another Fed Rate Cut

REGN

MT Newswires

18 days ago

Sector Update: Health Care Stocks Fall Late Afternoon

REGN

MT Newswires

18 days ago

JPMorgan Raises Price Target on Regeneron Pharmaceuticals to $850 From $800

REGN

Zacks

18 days ago

REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

REGN

GlobeNewswire

19 days ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

OncoNano Medicine Presents First-in-Human Data Demonstrating Safety and Early Signs of Clinical Activity of ONM-501, a Dual-Acting STING Agonist, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

REGN

Business Wire

20 days ago

OncoNano Medicine Presents First-in-Human Data Demonstrating Safety and Early Signs of Clinical Activity of ONM-501, a Dual-Acting STING Agonist, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

A Look at Regeneron Pharmaceuticals’s Valuation Following Key European Regulatory Win for Libtayo

REGN

Simply Wall St.

20 days ago

A Look at Regeneron Pharmaceuticals’s Valuation Following Key European Regulatory Win for Libtayo

REGN

StockStory

20 days ago

Regeneron Earnings: What To Look For From REGN

REGN

Insider Monkey

20 days ago

European Medicines Agency Adopts a Positive Opinion on Regeneron’s (REGN) Libtayo

REGN

Morningstar Research

22 days ago

Analyst Report: Sanofi

Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue

REGN

Investor's Business Daily

22 days ago

Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue

Fed Rate Move, Apple Earnings, Trump-Xi Meeting: What to Watch Next Week

REGN

The Wall Street Journal

22 days ago

Fed Rate Move, Apple Earnings, Trump-Xi Meeting: What to Watch Next Week

REGN

Insider Monkey

22 days ago

Long Leaf Partners Fund’s Comment on Regeneron (REGN)

REGN

Zacks

22 days ago

REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?

REGN

Zacks

23 days ago

Exploring Analyst Estimates for Regeneron (REGN) Q3 Earnings, Beyond Revenue and EPS

REGN

Zacks

25 days ago

Earnings Preview: Regeneron (REGN) Q3 Earnings Expected to Decline

The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.

REGN

Investor's Business Daily

a month ago

The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.

REGN

Simply Wall St.

a month ago

Is FDA and EMA Progress for Libtayo Transforming the Investment Story for Regeneron (REGN)?

REGN

MT Newswires

a month ago

Regeneron Says its Libtayo Adjuvant Treatment for Cutaneous Squamous Cell Carcinoma Recommended for EU Approval

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

REGN

GlobeNewswire

a month ago

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

REGN

Zacks

a month ago

REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss (Revised)

REGN

MT Newswires

a month ago

Rothschild & Co Redburn Adjusts Regeneron Pharmaceuticals Price Target to $900 From $890, Maintains Buy Rating

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

REGN

GlobeNewswire

a month ago

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

Regeneron’s Q3 2025 Earnings: What to Expect

REGN

Barchart

a month ago

Regeneron’s Q3 2025 Earnings: What to Expect

2 Stocks Down 17% and 21% to Buy Right Now

REGN

Motley Fool

a month ago

2 Stocks Down 17% and 21% to Buy Right Now

REGN

Zacks

a month ago

REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss

REGN

Insider Monkey

a month ago

Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge

Stock Market Today: Dow Jumps 400 Points On Trump Tariff Comments; Broadcom, Nvidia, Tesla Rally (Live Coverage)

REGN

Investor's Business Daily

a month ago

Stock Market Today: Dow Jumps 400 Points On Trump Tariff Comments; Broadcom, Nvidia, Tesla Rally (Live Coverage)

REGN

MT Newswires

a month ago

Regeneron Says Investigational Hearing Loss Therapy Shows Improvement in Almost All Study Participants

How Should Investors Value Regeneron After the 44% Stock Drop and DCF Surprise?

REGN

Simply Wall St.

a month ago

How Should Investors Value Regeneron After the 44% Stock Drop and DCF Surprise?

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

REGN

GlobeNewswire

a month ago

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy

REGN

BioPharma Dive

a month ago

Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

REGN

Investor's Business Daily

a month ago

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo

REGN

Zacks

a month ago

Regeneron Gets FDA Nod for Label Expansion of Oncology Drug Libtayo

Regeneron, needing a turnaround, gains new use for cancer drug

REGN

BioPharma Dive

a month ago

Regeneron, needing a turnaround, gains new use for cancer drug

Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab

REGN

GlobeNewswire

a month ago

Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab

REGN

MT Newswires

a month ago

Regeneron Says FDA Approved Libtayo as Immunotherapy for Adjuvant Treatment of High Risk Skin Cancer

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

REGN

GlobeNewswire

a month ago

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

REGN

MT Newswires

a month ago

RBC Raises Price Target on Regeneron Pharmaceuticals to $704 From $695, Keeps Sector Perform Rating

Cutaneous Squamous Cell Carcinoma Market Forecast Report 2025-2035, with Focus on Regeneron Pharmaceuticals, Sanofi, Merck & Co., Checkpoint Therapeutics, Incyte, and Sirnaomics

REGN

GlobeNewswire

a month ago

Cutaneous Squamous Cell Carcinoma Market Forecast Report 2025-2035, with Focus on Regeneron Pharmaceuticals, Sanofi, Merck & Co., Checkpoint Therapeutics, Incyte, and Sirnaomics

11 Cheap Stocks for a Market That’s Too Expensive

REGN

Barrons.com

a month ago

11 Cheap Stocks for a Market That’s Too Expensive

REGN

Simply Wall St.

a month ago

Regeneron (REGN): Reevaluating Valuation Following Breakthrough Trial Results and Evkeeza’s FDA Pediatric Approval

REGN

The Wall Street Journal

a month ago

Health Care Roundup: Market Talk

REGN

MT Newswires

a month ago

Sector Update: Health Care Stocks Retreat Late Afternoon

REGN

MT Newswires

a month ago

Sector Update: Health Care

REGN

MT Newswires

a month ago

Latest Regeneron Pharmaceuticals Inc. (REGN) News on November 15, 2025

Share on Social Networks: